36 results about "Cetuximab" patented technology

The invention discloses a novel nano-drug as well as a preparation method and application thereof, and co-delivery of siRNA and 3BP is realized on an exosome nano-platform, so that a novel nano-drug Exo (at) siRNA / 3BP-CTX (ERBC) engineering exosome is generated. The surface-modified cetuximab (CTX) is targeted to tumors, and shows high targeting and low toxicity in imaging analysis. CCK-8, western blot and immunofluorescence detection are used for detecting the tumor killing effect and the synergistic effect. The ERBC finds that the occurrence of death-promoting autophagy in KRAS mutation tumors is promoted on the transmission electron microscope (TEM) and molecular level.

The invention discloses antisense oligonucleotide for adjuvant therapy of oral squamous cell carcinoma and application of the antisense oligonucleotide. According to the invention, the rs737540 site and the mutant allele rs737540-T thereof are identified, so that the problem of lack of specific biomarkers and targeted therapy means in the prior art is solved. By designing the antisense oligonucleotide aiming at the rs737540 mutation site, selective splicing of TARDBP and EGFR exon 4 can be specifically blocked, and OSCC cell proliferation is inhibited. Besides, the EGFR targeted drug cetuximab is used in a combined manner, so that a stronger anti-cancer effect is realized, and the blank in the existing treatment means is filled. The core breakthrough of the technology is that genetic variation and targeted therapy are combined, and a new research thought and a clinical application prospect are provided for precise medicine of oral squamous cell carcinoma.

The invention relates to a preparation of an antibody drug, which belongs to the field of biological medicines, is used for a preparation of a high-concentration antibody drug with an anti-oxidation requirement, and also has an anti-degradation capability. The preparation contains 20 mmol / L to 30 mmol / L of L-methionine and 200 mmol / L of trehalose, and is particularly suitable for being used for preparing Jukoulikumab, omaszumab and cetuximab. The preparation not only has a better anti-oxidation effect, but also can realize a synergistic stabilization effect by combining high-concentration L-Met with 200 mM trehalose, has anti-degradation ability, is widely applicable to various therapeutic antibodies, and provides an extensible solution for improving the stability and shelf life of a high-concentration biological preparation.

The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and / or therapies and / or treatments for increasing production of a Cetuximab-like protein (CLP) by a subject that is administered the agent, therapy or treatment. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition that may benefit from reducing the DNA synthesis of genes that regulate cellular growth and proliferation.

The application belongs to the field of tumor molecular diagnosis and targeted therapy, and specifically finds lncRNA RP11-499F3.2 which is significantly highly expressed in head and neck cancer through bioinformatics analysis of TCGA data; it is verified through clinical samples that the expression level of RP11-499F3.2 in head and neck squamous cell carcinoma is significantly higher than that in paracancerous tissues, and is closely related to the clinical prognosis of patients with head and neck squamous cell carcinoma; it is found through functional experiments that high expression of RP11-499F3.2 can promote the in-vitro proliferation, migration and invasion of head and neck squamous cell carcinoma cells; meanwhile, it is also found that RP11-499F3.2 can promote the drug resistance of head and neck squamous cell carcinoma cells to cetuximab; the disclosed lncRNA RP11-499F3.2 helps to reveal the new pathogenesis of head and neck cancer, provides a new tumor marker for the prognosis monitoring of head and neck cancer, and provides a new idea for the clinical treatment of head and neck cancer.

Provided herein are combination therapies comprising a SHP2 inhibitor (e.g., Compound 1) and an EGFR inhibitor (e.g., osimertinib or cetuximab) and methods of using such combination therapies.

This application belongs to the field of analytical chemistry, and particularly relates to a method for detecting antibiotics in biological samples. This method uses liquid chromatography-mass spectrometry for detection, and has good specificity, accuracy, sensitivity, reliability and stability, and the detection limit and quantification limit are relatively low. It can be used to detect antibiotics (such as G418) in biological samples or biological products (such as cetuximab products) or intermediate products generated during their preparation or purification process.

The efficacy and indication of cetuximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The invention discloses a fluorescent nano-probe and a preparation method and application thereof in targeting oral and maxillofacial tumors, the CTX-TPD NPs fluorescent nano-probe comprises an amphiphilic polymer, TPD entrapped by the amphiphilic polymer and cetuximab modified outside the amphiphilic polymer, the amphiphilic polymer is a polymer composed of DSPE-PEG2000 and DSPE-PEG2000-COOH, the amphiphilic polymer is an amphiphilic polymer, the amphiphilic polymer is an amphiphilic polymer, the amphiphilic polymer is an amphiphilic polymer, and the amphiphilic polymer is an amphiphilic polymer. A DSPE part of the amphiphilic polymer is combined with TPD through hydrophobic interaction to form a hydrophobic core of the nanoparticle, a PEG chain segment of the amphiphilic polymer is distributed on the outer layer of the nanoparticle through hydrophilic interaction, and cetuximab is coupled to carboxyl of the PEG chain segment of the outer layer of the nanoparticle. The TPD molecule has breakthrough imaging performance, the AIE characteristic of the TPD molecule is enhanced in fluorescence in an aggregation state, the ACQ problem of a traditional dye is solved, and the imaging sensitivity is improved.

To provide effective cancer treatments. [Solution] The present invention provides a cancer treatment method that combines a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody), and standard therapy (e.g., combination therapy of FOLFOX therapy with bevacizumab or cetuximab for unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a reduced-dose regimen for pancreatic cancer with distant metastases).

The present invention relates to treatment of cancer using an anti-human ILT3 monoclonal antibody. The treatment may additionally comprise avelumab, nivolumab or cetuximab.

The invention relates to a heterodimer fusion protein and application thereof. The heterodimer fusion protein of the present invention comprises: a first heavy chain comprising a first Fc region and an immunomodulator fused to the first Fc region; a light chain and a second heavy chain, the second heavy chain comprising a second Fc region, the light chain and the second heavy chain being complexed to form a targeting moiety exhibiting binding specificity for tumor antigens or immune checkpoints; the light chain, the first heavy chain and the second heavy chain are compounded to form the heterodimer fusion protein. The heterodimer fusion protein disclosed by the invention can be used for targeted therapy of digestive tract cancer, especially colon cancer, and is good in targeting property, and the tumor inhibition effect of the heterodimer fusion protein is obviously superior to that of cetuximab with the same target point.

The present invention provides a kit for predicting the resistance of colorectal cancer patients to cetuximab or the efficacy of cetuximab, comprising reagents for detecting the level of asparaginyl endopeptidase (AEP) protein or the expression level of its encoding gene. The present invention also provides the use of an asparaginyl endopeptidase inhibitor in the preparation of a drug for preventing or treating cetuximab resistance in colorectal cancer, and a pharmaceutical composition for treating colorectal cancer comprising an asparaginyl endopeptidase inhibitor and cetuximab. The present invention discovers for the first time that AEP can be used as a specific marker for predicting the efficacy of cetuximab treatment in advanced colorectal cancer, and can be used as a therapeutic target for improving the resistance of intestinal cancer cells to cetuximab or enhancing the sensitivity of cetuximab.

The invention discloses a traditional Chinese medicine composition and a preparation method and application thereof.The traditional Chinese medicine composition comprises, by weight, 20-30 parts of dandelion, 20-30 parts of sophora flavescens, 30-100 parts of honeysuckle, 10-30 parts of radix paeoniae rubra and 20-30 parts of fructus kochiae, and the traditional Chinese medicine composition comprises, by weight, 20-30 parts of dandelion, 20-30 parts of sophora flavescens, 30-100 parts of honeysuckle, 10-30 parts of radix paeoniae rubra and 20-30 parts of fructus kochiae. The invention aims to obtain the medicine with the effect of efficiently treating rash caused by cetuximab injection medicine.

Provided include methods, compositions and kits for treating cancer (e.g., RASWT colorectal cancer) in a subject. The method can comprise administrating an a PLK1 inhibitor (for example, onvansertib) or a combination of a PLK1 inhibitor and an EGFR inhibitor to the subject in a manner sufficient to inhibit progression of the cancer.

The present invention relates to: an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 or an antigen-binding fragment thereof; and a pharmaceutical composition for treating cancer, comprising same as an active ingredient. The antibody-drug conjugate of the present invention comprises an antibody specifically targeting GRP94 and having strong internalization activity, and, as a result of conjugation with a cytotoxic agent, effectively inhibits the growth of cetuximab-resistant CRC cell lines including HT29, HCT116, HCT8 and LoVo cells, and thus can be effectively used as a therapeutic agent for various carcinomas in which GRP94 is overexpressed.

The invention described in the disclosure relates to a panel of biomarkers for determining the responsiveness of a cancer patient treated or to be treated by cetuximab. The disclosure provides methods and compositions, e.g., kits, for evaluating the biomarkers and methods of using such biomarkers to predict a cancer patient's response to cetuximab. Such information can be used in determining prognosis and treatment options for gastric cancer patients.

The present invention belongs to the field of biomedicine technology, and discloses a monoclonal antibody and a cytokine composition and its application. The light chain variable region sequence of the ZSCAN4 protein monoclonal antibody provided by the present invention is shown in SEQ ID NO.4, and the heavy chain variable region sequence is shown in SEQ ID NO.5. The cytokine is a cytokine secreted by bone marrow mesenchymal stem cells. In the monoclonal antibody and cytokine composition provided by the present invention, the ZSCAN4 protein monoclonal antibody can specifically bind to the human ZSCAN4 protein, and has the effect of reducing the vitality of colon cancer cells. After using it together with the cytokine, it can effectively reduce the number of colon cancer cell clones in a short time to treat colon cancer. The monoclonal antibody and cytokine composition provided by the present invention has a better inhibitory effect on colon cancer cells than cetuximab, and has a good prospect for medical application.

The invention belongs to the technical field of biomarkers, and particularly relates to detection for predicting responsiveness of colorectal cancer patients to cetuximab targeted therapy. The invention provides a novel lipid biomarker Cer d (18: 1 / 26: 0) and a corresponding detection method, aiming at solving the technical problems that the EGFR activation state cannot be directly reflected only by detecting gene mutation of downstream pathways such as KRAS / BRAF and the like, the detection method is large in invasiveness, high in cost and the like in the prior art, and the invention provides the novel lipid biomarker Cer d (18: 1 / 26: 0) and the corresponding detection method. The content of Cer d (18: 1 / 26: 0) in peripheral plasma of a colorectal cancer patient is detected, and the treatment responsiveness of the patient is judged according to a preset threshold value. Experimental results show that the content of Cer d (18: 1 / 26: 0) in tumors and plasma of CRC patients is remarkably increased, and the Cer d is closely related to the treatment effect of cetuximab. According to the scheme provided by the invention, the operation is simple and convenient, the wound is small, dynamic monitoring can be realized, and cetuximab treatment can be guided more accurately.

The invention discloses application of microRNA (Ribonucleic Acid) as a diagnostic marker in an advanced colorectal cancer drug resistance diagnostic kit and application of microRNA in preparation of drugs for treating advanced colorectal cancer. The invention discovers that miR-196b-5p is highly expressed in a cetuximab-sensitive intestinal cancer cell line, and the expression quantity of miR-196b-5p in a drug-resistant intestinal cancer cell line is generally low. The miR-196b-5p is subjected to an overexpression or knockout experiment, which proves that the miR-196b-5p can effectively influence the sensitivity of intestinal cancer cells to cetuximab. The miR-196b-5p is expected to become a novel biomarker for early prediction and screening of drug resistance of colorectal cancer patients using cetuximab, and assists in dynamic monitoring of curative effect and overcoming of drug resistance.

Provided include methods, compositions and kits for treating cancer (e.g., RASWT colorectal cancer) in a subject. The method can comprise administrating an a PLK1 inhibitor (for example, onvansertib) or a combination of a PLK1 inhibitor and an EGFR inhibitor to the subject in a manner sufficient to inhibit progression of the cancer.

The invention described in the disclosure relates to a panel of biomarkers for determining the responsiveness of a cancer patient treated or to be treated by cetuximab. The disclosure provides methods and compositions, e.g., kits, for evaluating the biomarkers and methods of using such biomarkers to predict a cancer patient's response to cetuximab. Such information can be used in determining prognosis and treatment options for gastric cancer patients.

Provided include methods, compositions and kits for treating cancer (e.g., RASWT colorectal cancer) in a subject. The method can comprise administrating an a PLK1 inhibitor (for example, onvansertib) or a combination of a PLK1 inhibitor and an EGFR inhibitor to the subject in a manner sufficient to inhibit progression of the cancer.

1. The name of the product of this design: Packaging box (Cetuximab β Injection - Enlito). 2. Purpose of this design product: This design product is used for pharmaceutical packaging. 3. The design key points of this appearance design product are: the combination of shape, pattern and color. 4. The picture or photo that best illustrates the key points of the design: main view. 5. The design for which protection is sought includes color.

Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.

To provide a pharmaceutical for treating KRasG12C mutant colorectal cancer.SOLUTION: The present invention provides a pharmaceutical for use in combination with a compound represented by the following formula and a chemical therapy comprising (i) cetuximab and (ii) FOLFOX (leucovorin, fluorouracil, and oxaliplatin) or FOLFIRI (leucovorin, fluorouracil, and irinotecan).SELECTED DRAWING: Figure 1

The application discloses a Fab-BH3 fusion protein and a preparation method and application thereof, belongs to the technical field of biological medicines, and particularly relates to a Fab-BH3 fusion protein, wherein the amino acid sequence of the Fab-BH3 fusion protein is shown as SEQ ID NO. 2. The application also discloses an application of the Fab-BH3 fusion protein in preparation of a drug for treating non-small cell lung cancer. The Fab-BH3 fusion protein is formed by coupling a cetuximab Fab fragment and a BH3 polypeptide, does not affect the activity of the cetuximab, inhibits the growth of non-small cell lung cancer cells with overexpressed EGFR, and improves the treatment effect on non-small cell lung cancer.

The invention discloses application of celecoxib and cetuximab in combined treatment of colorectal cancer with different KRAS genotypes, and belongs to the field of biological medicine. Celecoxib and cetuximab are combined for use, KRAS / Cdc42 / Neutrophil elatase and RAF-MEK-ERK pathways are inhibited, the sensitivity to cetuximab targeted therapy can be remarkably improved, the cetuximab targeted therapy composition is suitable for different KRAS genotype colorectal cancer including KRAS mutant colorectal cancer and KRAS wild colorectal cancer, the combined therapy effect is obviously superior to the curative effect of cetuximab, and the cetuximab targeted therapy composition is suitable for clinical application. A new thought is provided for the treatment of the intractable and drug-resistant colorectal cancer.

The invention discloses a Fab-BH3 fusion protein as well as a preparation method and application thereof, belongs to the technical field of biological medicines, and particularly relates to the Fab-BH3 fusion protein, and the amino acid sequence of the Fab-BH3 fusion protein is as shown in SEQ ID NO. 2. The invention further discloses application of the Fa-BH3 fusion protein in preparation of drugs for treating non-small cell lung cancer. According to the invention, the Fab fragment of the cetuximab and the BH3 polypeptide are coupled to form the Fa-BH3 fusion protein, the activity of the cetuximab is not influenced, and the Fa-BH3 fusion protein inhibits the growth of non-small cell lung cancer cells overexpressing EGFR, so that the treatment effect on the non-small cell lung cancer is improved.